These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 27475429)
1. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Ruella M; June CH Curr Hematol Malig Rep; 2016 Oct; 11(5):368-84. PubMed ID: 27475429 [TBL] [Abstract][Full Text] [Related]
2. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358 [TBL] [Abstract][Full Text] [Related]
3. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
16. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502 [TBL] [Abstract][Full Text] [Related]
17. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
18. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Avanzi MP; Brentjens RJ J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234 [TBL] [Abstract][Full Text] [Related]